Beta anomer comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-01. Numbers and descriptions here follow the published literature rather than marketing material.
NMN is present in small amounts in some foods, including certain vegetables, fruits, and animal products, but food content varies widely and is not well standardized. In laboratory research, NMN is used as a tool compound to study NAD+ metabolism, mitochondrial function, and cellular stress responses. Animal studies have reported changes in NAD+ levels and various physiological measures after NMN administration, but species differences and study designs limit direct extrapolation to humans. Human trials have largely focused on safety, tolerability, and pharmacokinetics, with fewer studies examining clinical endpoints.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
In the NAD+ salvage pathway, the enzyme NAMPT converts nicotinamide and a phosphate-donor molecule into NMN. A second enzyme, NMNAT, then converts NMN into NAD+. Nicotinamide riboside can also enter this route after being converted to NMN by nicotinamide riboside kinases. Because NMN sits at a junction between precursor uptake and NAD+ formation, its cellular concentration is tightly linked to enzyme activity and tissue type. NAD+ participates in redox reactions, signaling, and DNA repair, and its levels decline with age in some animal models, though human evidence remains more limited and context-dependent.
Research interest in NMN increased after animal studies reported that oral or injected NMN can raise NAD+ levels in some tissues. How NMN is absorbed and distributed in humans is not fully established. Some evidence suggests extracellular NMN may be dephosphorylated to nicotinamide riboside before cellular uptake, while other studies propose specific transport routes. Direct human data on these mechanisms remain limited. Regulatory status also varies: in some countries NMN is treated as a dietary supplement, while elsewhere it is restricted or requires approval, and these differences affect labeling, sale, and research.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C11H15N2O8P | Identifies the atoms in the nucleotide |
| Molar mass | 334.22 g/mol | Calculated from the molecular formula |
| Appearance | White to off-white powder | Typical for purified solid material |
| Solubility | Water-soluble | Polar nucleotide; less soluble in nonpolar solvents |
| Common synonyms | Nicotinamide mononucleotide; beta-NMN | beta-NMN refers to the common anomeric form |
Research on NMN has expanded because NAD+ concentrations decline with age in some tissues and because NAD+ participates in energy metabolism, DNA repair, and signaling. Animal studies have reported changes in NAD+ levels after NMN administration, but human data are more limited and often focus on safety, pharmacokinetics, and biomarker changes. Questions remain about oral absorption, tissue distribution, and whether changes in blood NAD+ reflect changes inside specific organs. NMN is not an approved drug, and claims about its clinical effects should be distinguished from established biochemical findings.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring, a ribose sugar, and a phosphate group. The compound exists in cells as an intermediate in the production of nicotinamide adenine dinucleotide, a central redox cofactor. NMN is distinct from nicotinamide riboside, another related pyridine nucleotide, although the two compounds can converge in metabolic pathways. Its chemical formula is C11H15N2O8P, and it carries a net negative charge at physiological pH.
Natural sources of NMN include mammals, plants, and microorganisms, where it functions as an intermediate in NAD+ salvage and biosynthesis pathways. In mammals, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase. Some foods contain measurable NMN, but reported amounts vary widely by species, tissue, and analytical method. The extent to which dietary NMN contributes to cellular NAD+ pools remains an open research question.
Chemically, NMN is described by the molecular formula C11H15N2O8P and a molecular mass near 334.22 g/mol. The beta anomer has a CAS Registry Number of 1094-61-7. It is typically supplied as a white to off-white powder for laboratory use. The molecule carries a phosphate group and a positively charged nicotinamide ring, giving it polar and water-soluble character. These properties influence how it is detected, purified, and stored in research and analytical laboratories.
Trace amounts of NMN have been reported in certain plant foods, including edamame, avocado, broccoli, cucumber, and cabbage. Reported concentrations vary widely because analytical methods differ and food matrices complicate extraction. Endogenous production in cells is generally considered more quantitatively important than dietary intake, though precise human turnover rates are difficult to establish. Commercial NMN for research or consumer products is commonly made through enzymatic synthesis or chemical phosphorylation routes. Regulatory classification differs by country; in some jurisdictions NMN is sold as a supplement, while in others it is treated as a novel food ingredient or restricted substance.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in cells. Its structure combines a nicotinamide ring, a ribose sugar, and a phosphate group. As an intermediate in the NAD+ salvage pathway, NMN is converted to nicotinamide adenine dinucleotide, a coenzyme central to cellular redox reactions. NAD+ also serves as a substrate for enzymes involved in DNA repair, stress responses, and metabolic regulation. The compound is therefore part of normal cellular biochemistry rather than an exclusively synthetic molecule.
NMN is present in small amounts in various foods, including certain vegetables, fruits, and milk, though dietary quantities are generally low. Laboratory research often uses synthetic or enzymatically produced NMN. The compound has drawn interest because NAD+ levels decline with age in some tissues and because restoring NAD+ may affect metabolism in animal models. Whether oral NMN produces meaningful NAD+ increases in humans and whether such changes translate into health benefits are not fully established.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide base with a ribose sugar and a phosphate group. Within cells, NMN sits on the biosynthetic route that recycles nicotinamide back into nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in redox reactions and signaling, enzymes that produce and consume it influence many metabolic processes. The compound is therefore best described as an intermediate rather than a final signaling molecule.
=== Deficiency === Decreased AVP release (neurogenic — i.e. due to alcohol intoxication or tumour) or decreased renal sensitivity to AVP (nephrogenic, i.e. by mutation of V2 receptor or AQP) leads to diabetes insipidus, a condition featuring hypernatremia (increased blood sodium concentration), polyuria (excess urine production), and polydipsia (thirst).
Sildenafil, sold under the brand name Viagra among others, is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is also sometimes used off-label for the treatment of certain symptoms in secondary Raynaud's phenomenon. It is unclear if it is effective for treating sexual dysfunction in females. It can be taken orally (swallowed by mouth), intravenously (injection into a vein), or through the sublingual route (dissolved under the tongue). Onset when taken orally is typically within twenty minutes and lasts for about two hours. Common side effects include headaches, heartburn, and flushed skin. Caution is advised in those with cardiovascular disease. Rare but serious side effects include vision problems, hearing loss, and prolonged erection (priapism) that can lead to damage to the penis. Sildenafil should not be taken by people on nitric oxide donors such as nitroglycerin, as this may result in a serious drop in blood pressure. Sildenafil acts by blocking phosphodiesterase 5 (PDE5), an enzyme that promotes breakdown of cGMP, which regulates blood flow in the penis. It requires sexual arousal to work, and does not by itself cause or increase sexual arousal. It also results in dilation of the blood vessels in the lungs. Pfizer originally discovered the medication in 1989 while looking for a treatment for angina. It was approved for medical use in the United States and in the European Union in 1998. In 2023, it was the 151st most commonly prescribed medication in the United States, with more than 3 million prescriptions.
Diabetic retinopathy, caused by alterations in retinal microcirculation, leading to the growth of friable and poor-quality new blood vessels in the retina or capillary closure which causes ischemia or extravasation of intravascular content, causing edema (swelling of the macula). Retinopathy is the most common cause of blindness among non-elderly adults in the developed world. Diabetic nephropathy, damage to the kidney due to increased glomerular pressure and hyperfiltration can lead to end-stage chronic kidney disease that may require renal dialysis. In most parts of the world, diabetes mellitus is the leading cause of end-stage kidney disease (ESKD). Diabetic nephropathy is increasingly recognized as a significant cause of ESKD in renal allograft recipients. Diabetic neuropathy, Neuropathies in diabetes may cause sensory, mononeuritis, and autonomic neuropathy symptoms, muscle weakness, and potentially life-threatening complications like diabetic foot syndrome (Diabetic amyotrophy) and myocardial infarctions. Intensive insulin therapy is recommended to reduce neuropathy risk, while oral antidiabetic drugs are recommended for pain treatment. Diabetic encephalopathy, Diabetes causes brain functional and structural disturbances, known as diabetic encephalopathy. Various mechanisms are proposed, like alterations to the vascular supply of the brain, or changes in cerebral function and structure, including cognitive impairment, cerebral signal conduction, neurotransmission, and synaptic plasticity are more insidious.
Observational documentaries attempt to spontaneously observe their subjects with minimal intervention. Filmmakers who worked in this subgenre often saw the poetic mode as too abstract and the expository mode as too didactic. The first observational docs date back to the 1960s; the technological developments that made them possible include mobile lightweight cameras and portable sound-recording equipment for synchronized sound. Often, this mode of film eschewed voice-over commentary, post-synchronized dialogue and music, or re-enactments. The films aimed for immediacy, intimacy, and revelation of individual human character in ordinary life situations.
Sources: en.wikipedia.org
=== Mayo Quadratic formula === Another estimation tool to calculate GFR is the Mayo Quadratic formula. This formula was developed by Rule et al., in an attempt to better estimate GFR in patients with preserved kidney function. It is well recognized that the MDRD formula tends to underestimate GFR in patients with preserved kidney function. Studies in 2008 found that the Mayo Clinic Quadratic Equation compared moderately well with radionuclide GFR, but had inferior bias and accuracy than the MDRD equation in a clinical setting. The equation is:
UNICEF spokesperson Toby Fricker stated, "There is no safe place for children anywhere across the strip right now." On 19 December, the United Nations stated Gaza was "by far the most dangerous place in the world to be a child". James Elder, a UNICEF spokesperson, called the conflict in Gaza a "war on children." On 6 January 2024, Tanya Haj-Hassan, a doctor with Doctors Without Borders, stated children in Gaza were "dying in every way possible." On 18 January 2024, the deputy executive director of UNICEF stated the suffering of children in Gaza were the "most horrific conditions I have ever seen." On 2 February 2024, the UNICEF chair stated, "The situation for children in Gaza grows bleaker every day. The world cannot abandon them." On 5 March, UNICEF called the war on Gaza "a test of human conscience" and stated that the lack of humanitarian aid in the north was worsening children's health situation. Adele Khodr, UNICEF's Middle East regional director, stated on 19 March: "The world’s inaction is shocking as more children succumb to a slow death."
Tarlov concluded that such cysts, though often overlooked during standard imaging or surgery, could produce clinically significant symptoms and should be considered in cases of unexplained sciatic pain. He published these findings in the paper "Cysts (Perineurial) of the Sacral Roots: Another Cause (Removable) of Sciatic Pain" (1948). In 1952, Tarlov published his third paper on perineurial cysts, titled "Cysts of the Sacral Nerve Roots: Clinical Significance and Pathogenesis". In this work, he acknowledged the limitations of his earlier cadaver studies due to incomplete medical records, noting that the symptomatic relevance of the cysts was initially unclear. The paper presented detailed accounts of two surgical cases from 1950 and 1951 in which sacral nerve root cysts were associated with neurological symptoms. The first patient, a 28-year-old man with progressive numbness, urinary incontinence, and sexual dysfunction, was found to have bilateral S2 cysts; surgical removal of the right cyst and drainage of the left halted symptom progression and improved bladder function. The second case involved a 70-year-old woman with paresthesia in the right leg and vaginal area, foot weakness, and sacral tenderness, in whom four cysts were discovered on the S2 and S3 nerve roots. Partial excision led to improvement in foot strength and partial symptom relief. Tarlov also discussed two post-mortem cases in which subarachnoid hemorrhages and sacral cysts coexisted, prompting the hypothesis that the cysts might occasionally form secondary to hemorrhagic damage to nerve roots.
=== "Central pillar" cave structure === In the typical "central pillar" design, pilgrims can circumambulate around a central column incorporating a niche for a statue of the Buddha, which is a representation of the stupa. The so-called "central pillar" which appears on a plan is actually not a pillar at all but only the rock at the back of the cave, into which was bored a circular corridor allowing for circumambulation. A large vaulted chamber is located in front of the "central pillar" column and a smaller rear chamber behind with two tunnel-like corridors on the sides linking these spaces. In the front chamber, a three-dimensional image of Buddha would have been housed in a large niche serving as the focus of the interior, however, none of these sculptures have survived at Kizil. The rear chamber may feature the parinirvana scene in the form of a mural or large sculpture, and in some cases, a combination of both. The "central pillar" layout is possibly related to the structural design of Kara Tepe in northern Bactria. The program of the paintings in the "central pillar" caves generally follows a fixed arrangement: the walls of the main cella show sermons of the Buddha, the ceiling has rhomboid vignettes alluding to Jatakas, the central niche has the scene of the Indrasala Cave. The back room or corridor has scenes related to the Parinirvana, and finally the painting over the exit is related to the Tusita Heaven and the future Buddha Maitreya.
== Bibliography == Corson, D. R.; MacKenzie, K. R.; Segrè, E. (1940). "Artificially Radioactive Element 85". Physical Review. 58 (8): 672–678. Bibcode:1940PhRv...58..672C. doi:10.1103/PhysRev.58.672. (subscription required) Greenwood, N. N.; Earnshaw, A. (2002). Chemistry of the Elements (2nd ed.). Butterworth-Heinemann. ISBN 978-0-7506-3365-9. Kugler, H. K.; Keller, C. (1985). 'At, Astatine', System No. 8a. Gmelin Handbook of Inorganic and Organometallic Chemistry. Vol. 8 (8th ed.). Springer-Verlag. ISBN 978-3-540-93516-2. Lavrukhina, Avgusta Konstantinovna; Pozdnyakov, Aleksandr Aleksandrovich (1970). Analytical Chemistry of Technetium, Promethium, Astatine, and Francium. Translated by R. Kondor. Ann Arbor–Humphrey Science Publishers. ISBN 978-0-250-39923-9. Scerri, Eric (2013). A Tale of Seven Elements. Oxford University Press, ISBN 9780195391312. Vértes, A.; Nagy, S.; Klencsár, Z. (2003). Handbook of Nuclear Chemistry. Vol. 4. Springer. ISBN 978-1-4020-1316-4. Zuckerman, J. J.; Hagen, A. P. (1989). Inorganic Reactions and Methods, Volume 3, The Formation of Bonds to Halogens (Part 1). John Wiley & Sons. ISBN 978-0-471-18656-4. Zuckerman, J. J.; Hagen, A. P. (1990). Inorganic Reactions and Methods, Volume 4, The Formation of Bonds to Halogens (Part 2). John Wiley & Sons. ISBN 978-0-471-18657-1.
Sources: en.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a nucleotide intermediate in the cellular pathway that produces NAD+, a coenzyme involved in energy metabolism and signaling. NMN is not the same compound as NAD+.
NMN is a direct precursor to NAD+ in the salvage pathway. The enzyme NMNAT converts NMN into NAD+ by adding an adenine nucleotide group. This relationship is why NMN is studied in the context of NAD+ decline.
Yes, NMN is produced naturally in cells as part of NAD+ recycling. It also appears in small and variable amounts in some foods. Its natural presence does not by itself establish that supplemental NMN has clinical benefits.
Nicotinamide mononucleotide is a nucleotide intermediate in the biosynthesis of NAD+. It consists of nicotinamide attached to a ribose phosphate unit. NMN occurs naturally in cells and is present at low levels in some foods.